Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
Use of anthropogenic-related nest material and nest parasite prevalence have increased over the past two centuries in Australian birds.
Potvin DA, Opitz F, Townsend KA, Knutie SA. Potvin DA, et al. Oecologia. 2021 Aug;196(4):1207-1217. doi: 10.1007/s00442-021-04982-z. Epub 2021 Jul 8. Oecologia. 2021. PMID: 34236465
Recent studies have shown that birds incorporate anthropogenic debris into their nests, which can reduce nest ectoparasite loads. However, we know little about the long-term history of interactions among birds, anthropogenic debris, and ectoparasites. ...
Recent studies have shown that birds incorporate anthropogenic debris into their nests, which can reduce nest ectoparasite loads. However, w …
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
Allas S, Caixàs A, Poitou C, Coupaye M, Thuilleaux D, Lorenzini F, Diene G, Crinò A, Illouz F, Grugni G, Potvin D, Bocchini S, Delale T, Abribat T, Tauber M. Allas S, et al. Among authors: potvin d. PLoS One. 2018 Jan 10;13(1):e0190849. doi: 10.1371/journal.pone.0190849. eCollection 2018. PLoS One. 2018. PMID: 29320575 Free PMC article. Clinical Trial.
CONCLUSIONS: AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic issues in patients with PWS. These findings support further investigation in longer-term clinical trials....
CONCLUSIONS: AZP-531 may constitute a new treatment strategy to improve hyperphagia and metabolic issues in patients with PWS. These finding …
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A. Batlevi CL, et al. Among authors: potvin d. Br J Haematol. 2017 Aug;178(3):434-441. doi: 10.1111/bjh.14698. Epub 2017 Apr 25. Br J Haematol. 2017. PMID: 28440559 Free PMC article. Clinical Trial.
Although mocetinostat had limited single-agent activity in R/R DLBCL and FL, patients with clinical benefit had long-term disease control. The safety profile was acceptable. This drug class warrants further investigation, including identifying patients more likely to respo …
Although mocetinostat had limited single-agent activity in R/R DLBCL and FL, patients with clinical benefit had long-term disease con …
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Falutz J, et al. Among authors: potvin d. AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058. AIDS. 2008. PMID: 18690162 Clinical Trial.
The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin. DESIGN: HIV patients with central fat accumulation in the context of antiretroviral therapy were randomized to tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. dai …
The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin. DESIGN: HIV patients with c …
Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J. Lambert M, et al. Among authors: potvin d. Pediatrics. 1996 May;97(5):619-28. Pediatrics. 1996. PMID: 8628597 Clinical Trial.
Therefore, our objectives were to determine the efficacy, safety, and tolerance of the short-term use of lovastatin, a 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitor, in the control of severe FH in a male pediatric population and to evaluate the dose-response re …
Therefore, our objectives were to determine the efficacy, safety, and tolerance of the short-term use of lovastatin, a 3-hydroxy 3-me …